

Iowa Medicaid Pharmaceutical and Therapeutics Committee Minutes

Date: August 21, 2025

Chairperson: Jason Kruse

Time: 9:30 a.m. to 12:02 p.m.

Location: Virtual through Zoom

Committee Members Present: Jason Kruse, D.O.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D.; Tricia McComb, R.N.; Dawn Schissel, M.D.; Fadi Yacoub, M.D.; Charles Wadle, D.O.; and Jennifer Doudna, Pharm.D., R.Ph. (Vacancies July 2023: 1 Physician Assistant)

Committee Members Absent: None

Iowa DHHS Staff Present: Abby Cate, Pharm.D., Pharmacy Consultant; and Darian Forcier, Pharmacy Administrative Support.

Iowa Medicaid Staff Present: Roberta Capp, M.D., MHS; Paige Clayton, Pharm.D.; Erin Halverson, R.Ph.; Gina Kuebler, R.Ph.; Pam Smith, R.Ph.; and Melissa Biddle.

Managed Care Organization (MCO) Staff Present: Jordan Thoman, Wellpoint Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa.

Jason Kruse called the meeting to order.

- I. Jason Kruse asked that each committee member introduce themselves to the public. Dawn Schissel made the motion to approve the April minutes, and Fadi Yacoub seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures.
- II. PDL Revision Notifications (Erin Halverson): Providers have received one notice since the last committee meeting. Due to the discontinuation of Nuvaring, etonogestrel-ee vaginal ring will be preferred on the Iowa Medicaid Preferred Drug List (PDL).
- III. Drug Rebate Issues (Dr. Clayton): There are no current issues to report. The Federal “Big Beautiful Bill” that was passed does have implications for Medicaid Pharmacy programs that could cause issues down the road, but there is nothing immediately pressing that needs to be done in response to that legislation or any recent tariff updates. The annual Sovereign States Drug Consortium (SSDC) Meeting in July went well, and resulting contract offers for calendar year 2026 will be reviewed at the November P&T Meeting.
- IV. PA Criteria/Pro-DUR Edits (Dr. Cate): Committee members were provided copies of Informational Letters 2685-MC-FFS-D and 2686-MC-FFS-D sent to providers notifying them of Pharmacy Program and PDL changes since the last meeting. The committee also received copies of the letters sent from the DUR Commission to DHHS following their meetings on May 7th and

August 6th, which had recommended changes to the prior authorization criteria for: Aprepitant (Tryvion); CNS Stimulants and Atomoxetine; Letermovir (Prevymis); Peanut (Arachis hypogaea) Allergen Powder-DNFP (Palforzia); Oxybate Products; Tirzepatide (Zepbound) for OSA; removal of PA criteria for Direct Oral Anticoagulants; a ProDUR quantity limit for Eliquis; Adenosine Triphosphate-Citrate Lyase (ACL) Inhibitors; Anti-Diabetic Non-Insulin Agents; Dupilumab (Dupixent); Givinostat (Duvyzat); IL-5 Antagonists; Janus Kinase (JAK) Inhibitors; Lebrikizumab-lbkz (Ebglyss); Nemolizumab-ilto (Nemluvio); Olezarsen (Tryngolza); Omalizumab (Xolair); and Palopegteriparatide (Yorvipath). Additionally, the DUR Commission recommends a ProDUR edit for the concurrent use of a DPP-4 inhibitor containing agent with a GLP-1 receptor agonist containing agent.

- V. Legislation (Dr. Cate): The dispensing fee increase was not approved with the DHHS appropriations bill, so it will remain \$10.63 per prescription.
- VI. Iowa Medicaid Updates (Dr. Cate): Lee Grossman will be the new Medicaid Director, effective September 2, 2025. He is an Iowa native and has been working for Wyoming Medicaid for the past 14 years.
- VII. Public Comment: In addition to the written public comments provided to committee members, they heard oral public comments from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

Name	Organization / Manufacturer	Product
Lauren Sumner	Sanofi	Qfitlia
Jasmine Inman	Teva	Simlandi and Selarsdi
Taha Khan	Vertex	Journavx
Chris Dietrich	ARS Pharmaceuticals	Neffy
Tania Gregorian	BridgeBio	Attruby
Asma Sikder	Axsome Therapeutics	Symbravo
Sarah Bellefeuille	Novo Nordisk	Wegovy
Audrey Nguyen	Springworks Therapeutics	Gomekli
Kristen Duffey	Novartis	Vanrafia
Rick Melbye	UCB	Bimzelx
Elizabeth Lubelczyk	Eli Lilly and Company	Ebglyss

Member Comments Received: None

Written Provider Comments Received: Symbravo

Written Manufacturer Comments Received: Sevenfact

At 10:26, Chuck Wadle motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. Dawn Schissel seconded, and the motion passed with unanimous roll call approval. Open session resumed at 11:06.

VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.

1. Neffy nasal spray to Preferred
2. Buspirone 30mg tablets to Preferred
3. Ofloxacin ophthalmic solution to Preferred
4. Doxycycline hyclate 50mg & 100mg capsules to Preferred
5. Doxycycline hyclate 20mg & 100mg tablets to Preferred
6. Doxycycline monohydrate 50mg & 100mg tablets to Preferred
7. Nystatin cream to Preferred

Fadi Yacoub motioned to accept the recommendations above, and Dawn Schissel seconded. The decision was unanimous.

IX. Newly Released Drugs (Dr. Capp and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted. Dr. Capp reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Attruby- Recommend status on the PDL as Non-Preferred
2. Avmapki Fakzynja CO-PACK- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
3. Ebglyss- Recommend status on the PDL as Preferred with Conditions
4. Gomekli- Recommend status on the PDL as Non-Preferred
5. Itovebi- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
6. Journavx- Recommend status on the PDL as Preferred (qty limit 14-day supply per 60 days)
7. Nemludio- Recommend status on the PDL as Non-Preferred with Conditions
8. Qfitlia- Recommend status on the PDL as Non-Preferred
9. Revuforj- Recommend status on the RDL as Non-Recommended with Conditions (Select Oncology Agents)
10. Romvimza- Recommend status on the PDL as Non-Recommended with Conditions (Select Oncology Agents)
11. Sofdra- Recommend status on the PDL as Non-Preferred
12. Tryngolza- Recommend status on the PDL as Non-Preferred
13. Vanrafia- Recommend status on the PDL as Non-Preferred

Fadi Yacoub motioned to accept the recommendations above. Dawn Schissel seconded, and the decision was unanimous.

X. Newly Released Generic Drugs and New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Auranofin	Non-Preferred
Chenodal	Non-Preferred
Eltrombopag	Non-Preferred with Conditions
Emtricitabine-Rilpivirine-Tenofovir	Non-Preferred
Eslicarbazepine	Non-Preferred
Exenatide	Non-Preferred with Conditions
Nilotinib	Non-Preferred with Conditions
Perampanel	Non-Preferred
Rivaroxaban	Non-Preferred
Ticagrelor	Non-Preferred
Umeclidinium-Vilanterol	Non-Preferred
Ustekinumab	Non-Preferred with Conditions
Ustekinumab-aekn	Non-Preferred with Conditions
Ustekinumab-ttwe	Non-Preferred with Conditions

Fadi Yacoub motioned to accept the recommendations in the table above. Dawn Schissel seconded, and all members were in favor.

Drug Name	PDL/RDL Recommendation
Adalimumab-ryvk	Non-Preferred with Conditions
Bucapsol	Non-Preferred
Edurant Ped Tab	Preferred
Evrysdi Tabs	Non-Preferred with Conditions
Hemiclor	Non-Preferred
Inzirqo	Non-Preferred
Ivermectin 6mg	Non-Preferred
Khindivi Oral Solution	Non-Preferred
Onapgo	Non-Preferred
Raldesy Oral Solution	Non-Preferred
Renthyroid	Non-Preferred
Symbravo	Non-Preferred with Conditions
Tezruly Oral Solution	Non-Preferred
Vyvgart Hytrulo	Non-Preferred
Xromi Oral Solution	Non-Preferred

Fadi Yacoub motioned to accept the recommendations in both tables above. Lacey Ferguson seconded, and all members were in favor.

- XI. Hemophilia Treatment Staff Presentation: Dr. Capp presented a PowerPoint outlining treatment for Hemophilia A and B.

A motion was made by Fadi Yacoub to adjourn the meeting. It was seconded by Dawn Schissel, and all in attendance approved. The meeting adjourned at 12:02 p.m. The next scheduled meeting is set for November 20, 2025.